Trials / Completed
CompletedNCT00239629
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 73 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to directly compare the bone forming effects of 20 microg/day of teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric variables and biochemical bone formation markers after 6 months of therapy in postmenopausal women with osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide | |
| DRUG | Strontium ranelate | |
| PROCEDURE | Transiliac bone biopsy |
Timeline
- Start date
- 2005-09-01
- Completion
- 2007-01-01
- First posted
- 2005-10-17
- Last updated
- 2007-06-12
Locations
11 sites across 6 countries: Czechia, Germany, Greece, Israel, Mexico, Spain
Source: ClinicalTrials.gov record NCT00239629. Inclusion in this directory is not an endorsement.